Patents by Inventor B. Kim Lee Sim
B. Kim Lee Sim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220323562Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: ApplicationFiled: April 25, 2022Publication date: October 13, 2022Inventors: Yun WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN
-
Patent number: 11324814Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: GrantFiled: June 10, 2020Date of Patent: May 10, 2022Assignee: Protein Potential, LLCInventors: Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
-
Publication number: 20200376107Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: ApplicationFiled: June 10, 2020Publication date: December 3, 2020Applicant: Protein Potential, LLCInventors: Yun WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN
-
Patent number: 10695415Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: GrantFiled: July 6, 2016Date of Patent: June 30, 2020Assignee: Protein Potential, LLCInventors: Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
-
Patent number: 10272146Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: March 14, 2017Date of Patent: April 30, 2019Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20180264099Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: ApplicationFiled: July 6, 2016Publication date: September 20, 2018Applicant: Protein Potential, LLCInventors: YUN WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN
-
Publication number: 20170274061Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: March 14, 2017Publication date: September 28, 2017Applicant: Sanaria Inc.Inventors: B. Kim Lee SIM, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Patent number: 9616115Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: January 21, 2016Date of Patent: April 11, 2017Assignee: SANARIA INC.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20160175417Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: January 21, 2016Publication date: June 23, 2016Applicant: Sanaria Inc.Inventors: B. Kim Lee SIM, Minglin LI, Richard E. STAFFORD, Stephen L. HOFFMAN
-
Patent number: 9241982Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: March 27, 2015Date of Patent: January 26, 2016Assignee: SANARIA INC.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20150313981Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: March 27, 2015Publication date: November 5, 2015Applicant: Sanaria Inc.Inventors: B. Kim Lee SIM, Minglin LI, Richard E. STAFFORD, Stephen L. Hoffman
-
Patent number: 8992944Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: December 28, 2012Date of Patent: March 31, 2015Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Patent number: 8821896Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: December 28, 2012Date of Patent: September 2, 2014Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20130251750Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: December 28, 2012Publication date: September 26, 2013Applicant: Sanaria Inc.Inventors: B. Kim Lee SIM, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Patent number: 8367810Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: August 27, 2010Date of Patent: February 5, 2013Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20120058543Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: August 27, 2010Publication date: March 8, 2012Applicant: Sanaria, Inc.Inventors: B. Kim Lee SIM, Minglin Li, Richard E. STAFFORD, Stephen L. HOFFMAN
-
Patent number: 8043625Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: January 8, 2010Date of Patent: October 25, 2011Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20100183680Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: January 8, 2010Publication date: July 22, 2010Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Patent number: 7078507Abstract: Synthetic gene sequences encoding erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into the DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both.Type: GrantFiled: November 12, 2002Date of Patent: July 18, 2006Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: David Narum, Hong Liang, Steve Fuhrmann, B. Kim Lee Sim
-
Publication number: 20040022805Abstract: Synthetic gene sequences encoding erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into the DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both.Type: ApplicationFiled: November 12, 2002Publication date: February 5, 2004Inventors: David Narum, Hong Liang, Steve Fuhrmann, B. Kim Lee Sim